焦磷酸测序技术检测SLCO1B1基因多态性方法的建立

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (5): 543-548.

焦磷酸测序技术检测SLCO1B1基因多态性方法的建立

万子睿¹, 谢海棠², 郭栋¹, 胡东莉¹, 王丽萍¹, 王果¹

¹中南大学临床药理研究所,长沙 410078,湖南;
²皖南医学院弋矶山医院临床药学部,安徽省药物临床评价中心,芜湖　241001,安徽

收稿日期:2011-12-20 修回日期:2012-02-06 出版日期:2012-05-26 发布日期:2012-05-28
通讯作者: 王果,男,副教授,主要从事遗传药理和临床药理学研究。Tel: 0731-84805380 E-mail: wangguo30@yahoo.com.cn
作者简介:万子睿,男,硕士研究生,主要从事遗传药理和临床药理学研究。E-mail: maxim_w@163.com
基金资助:
国家自然科学基金项目(81072706, 81173134);高等学校博士学科点专项科研基金资助课题(20090162120024);湖南省科技计划项目(2009JT3020)

Development of pyrosequencing method for detection of SLCO1B1 polymorphisms

WAN Zi-rui¹, XIE Hai-tang², GUO Dong¹, HU Dong-li¹, WANG Li-ping¹, WANG Guo¹

¹Institute of Clinical Pharmacology, Central South University, Changsha 410078, Hunan, China;
²Institute of Clinical Pharmacy and Pharmacology, Yijishan Hospital of Wanan Medical College, Anhui Provincial Center for Drug Clinical Evaluation, Wuhu 241001, Anhui, China

Received:2011-12-20 Revised:2012-02-06 Online:2012-05-26 Published:2012-05-28

摘要/Abstract

摘要： 目的:建立SLCO1B1 A388G和T521C单核苷酸多态位点的焦磷酸测序方法,分析中国健康人群中分布频率。方法: 制备300例健康人外周血gDNA,应用PyroMark ID焦磷酸测序仪进行多态位点分型分析。并通过重复性检验和毛细管电泳测序验证方法正确性。结果: 建立了SLCO1B1 A388G和T521C多态性分析的焦磷酸测序新方法,经毛细管电泳测序验证和重复性验证,结果准确可靠。在300例标本中, 388A、388G、521T、521C等位基因频率分别为28%、72%、89.5%和 10.5%,符合Hardy-Weinberg平衡。结论:焦磷酸测序方法可准确、高通量、快速检测SLCO1B1 A388G和T521C单核苷酸多态性,特别适宜大样本量的临床及科研批量检测需要。

关键词: 焦磷酸测序, SLCO1B1, OATP1B1, 单核苷酸多态性

Abstract: AIM: To establish a pyrosequencing based method for detection SLCO1B1 A388G and T521C polymorphisms and to determine the frequency of these polymorphisms in healthy Chinese.METHODS: After preparation of gDNA from blood of 300 subjects, the target fragments were amplified by PCR, polymorphisms were detected on PyroMark ID by pyrosequencing technology. The reliability of pyrosequencing methods were validated by repeat tests and Sanger sequencing.RESULTS:We established a new pyrosequencing method to detect the SLCO1B1 A388G and T521C polymorphisms polymorphisms in healthy Chinese. The detection rate and repetition rate were both 100%. The frequencies of 388A, 388G, 521T and 521C alleles were 28%,72%,89.5% and 10.5%, respectively. Genotype frequencies match the Hardy-Weinberg equilibrium.CONCLUSION: These pyrosequencing assays to detect SLCO1B1 polymorphisms are proved to be a rapid, accurate and high-throughput alternative to conventional methods, and it can be a preferred option in research and clinical application.

中图分类号:

R968

万子睿, 谢海棠, 郭栋, 胡东莉, 王丽萍, 王果. 焦磷酸测序技术检测SLCO1B1基因多态性方法的建立[J]. 中国临床药理学与治疗学, 2012, 17(5): 543-548.

WAN Zi-rui, XIE Hai-tang, GUO Dong, HU Dong-li, WANG Li-ping, WANG Guo. Development of pyrosequencing method for detection of SLCO1B1 polymorphisms[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(5): 543-548.

参考文献

[1] Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties[J]. Pflugers Arch, 2004, 447 (5):653-665.
[2] Nozawa T, Nakajima M, Tamai I, et al. Genetic polymorphisms of human organic anion transporters OATP2C (SLC21A6) and OATP2B (SLC21A9): allele frequencies in the Japanese population and functional analysis[J]. J Pharm Acol Exp Ther, 2002, 302(2):804- 813.
[3] Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide2C (OATP2C , SLCO1B1)[J]. Pharmacogenetics, 2004, 14 (7):429-440.
[4] Kalliokoski A, Neuvonen M, Neuvonen PJ, et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide[J]. J Clin Pharmacol, 2008, 48(3): 311-321.
[5] Kalliokoski A, Backman JT, Kurkinen KJ, et al. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism[J]. Clin Pharmacol Ther, 2008, 84(4):488-496.
[6] Kalliokoski A, Neuvonen M, Neuvonen PJ, et al. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range[J]. Br J Clin Pharmacol, 2008, 66(6): 818-825.
[7] Ho RH, Choi L, Lee W, et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants[J]. Pharmacogenet Genomics, 2007, 17(8):647-656.
[8] Mwinyi J, Johne A, Bauer S, et al. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics[J]. Clin Pharmacol Ther, 2004, 75(5): 415-421.
[9] 翟仙敦, 刘之江, 侯一平. 焦磷酸测序技术及其法医学应用[J]. 中国司法鉴定, 2009, 4: 39-42.
[10] 赵钢涛, 丁媛媛, 杨凡, 等. Pyrosequencing检测CYP2C9^*3基因多态性方法的建立及其可靠性研究[J]. 中国临床药理学与治疗学, 2009, 14(7): 799-803.
[11] 朱利军, 李定云, 李智, 等. 焦磷酸测序技术快速测定肾移植受体人群CYP3A5*3 基因多态性方法的建立[J]. 中国现代医学杂志, 2010, 20(15): 2302-2306.
[12] 贾政军, 王华, 彭向京, 等. 焦磷酸测序技术检测LAMA5 rs944895基因多态性方法的建立[J]. 中国临床药理学与治疗学, 2011, 16 (6): 647-651.
[13] 温爱萍, 徐小薇, 严晓伟. 有机阴离子转运多肽1B1遗传多态性对普伐他汀药动学的影响[J]. 中国药学杂志, 2008, 43(22):1735-1739.
[14] Thompson JF, Man M, Johnson KJ, et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response[J]. Pharmacogenomics J, 2005, 5(6): 352-358.
[15] Xiang X, Jada SR, Li HH, et al. Pharmacogenetics of SLCO1B1 gene and the impact of ^*1b and ^*15 haplotypes on irinotecan disposition in Asian cancer patients[J]. Pharmacogenet Genomics, 2006, 16(9): 683-691.